Table 2 |
||||||||||||||
|
Clinical features at diagnosis of patients with myopathy related to systemic sclerosis |
||||||||||||||
|
N° |
Type |
Antibody |
At baseline |
At diagnosis |
||||||||||
|
Aldolase (0 to 7 U/L) |
AST (0 to 32 U/L) |
ALT (0 to 32 U/L) |
CK (0 to 160 U/L) |
8MMT (0 to 80) |
Aldolase (0 to 7 U/L) |
AST (0 to 32 U/L) |
ALT (0 to 32 U/L) |
CK (0 to 160 U/L) |
EMG |
Thigh muscle RMI |
Muscular biopsy |
|||
|
|
||||||||||||||
|
1 |
dSSc |
ATA |
16 |
38 |
12 |
34 |
66 |
19 |
172 |
49 |
800 |
+ |
- |
+ |
|
2 |
dSSc |
ATA |
9 |
35 |
20 |
11 |
60 |
9.7 |
58 |
28 |
234 |
+ |
- |
+ |
|
3 |
lSSc |
ACA |
15.8 |
36 |
24 |
25 |
64 |
40 |
86 |
32 |
100 |
- |
+ |
+ |
|
4 |
lSSc |
ATA |
23.5 |
25 |
31 |
31 |
55 |
9.3 |
53 |
25 |
364 |
+ |
+ |
+ |
|
5 |
lSSc |
ACA |
29 |
55 |
54 |
18 |
68 |
37.2 |
962 |
22 |
1,180 |
+ |
+ |
+ |
|
6 |
dSSc |
ATA PM-Scl |
9.3 |
56 |
29 |
36 |
66 |
22.4 |
122 |
99 |
254 |
+ |
+ |
+ |
|
7 |
dSSc |
ATA U3-RNP |
16.2 |
54 |
14 |
21 |
68 |
17.8 |
109 |
52 |
271 |
+ |
+ |
+ |
|
8 |
lSSc |
ACA |
13.6 |
50 |
16 |
19 |
64 |
24.8 |
173 |
96 |
40 |
+ |
+ |
ND |
|
9 |
dSSc |
0 |
11.6 |
14 |
15 |
14 |
69 |
9.1 |
57 |
20 |
28 |
+ |
+ |
ND |
|
|
||||||||||||||
|
+ means the presence of abnormalities described as criteria of myositis according to the EMNC (5); ACA, Anti-centromere antibodiy; ATA, Anti-topoisomerase I antibody; CK, creatine kinase; dSSc, diffuse form of systemic sclerosis; all patients had antinuclear antibody positive; EMG, electromyography; lSSc, limited cutaneous form of systemic sclerosis; ND, not done; PM-Scl, anti- polymyositis-scleroderma antibody; RMI, resonance magnetic imaging; U3-RNP, Anti U3-RNP antibody; Yrs, years |
||||||||||||||
|
Tolédano et al. Arthritis Research & Therapy 2012 14:R152 doi:10.1186/ar3888 |
||||||||||||||
